Bicalutamide

• CAT Number: A000982
• CAS Number: 90357-06-5
• Molecular Formula: C18H14F4N2O4S
• Molecular Weight: 430.40
• Purity: ≥95%
• Synonyms: 90357-06-5; Casodex; Cosudex; Calutide; ICI 176334
• Target: Autophagy
• Solubility: >21.5mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
• InChI: InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
• InChIKey: LKJPYSCBVHEWIU-UHFFFAOYSA-N
• SMILES: CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O

Bicalutamide（Cat No.:A000982）is a non-steroidal antiandrogen with the molecular formula C18H14F4N2O4S, primarily used to treat prostate cancer. It works by competitively inhibiting androgen receptors, blocking the action of male hormones like testosterone, which can promote the growth of prostate cancer cells. Bicalutamide is usually administered orally in combination with luteinizing hormone-releasing hormone (LHRH) analogs for advanced or metastatic prostate cancer. It is generally well-tolerated, with common side effects including hot flashes, gynecomastia, fatigue, and gastrointestinal discomfort. Its selective action allows for effective hormonal therapy with a favorable safety profile.